224 related articles for article (PubMed ID: 2509641)
1. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
2. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
[TBL] [Abstract][Full Text] [Related]
4. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
5. Gynecologic Oncology Group experience with ifosfamide.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; Malfetano JH
Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
[TBL] [Abstract][Full Text] [Related]
10. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Sutton G; Blessing JA; Park R; DiSaia PJ; Rosenshein N
Obstet Gynecol; 1996 May; 87(5 Pt 1):747-50. PubMed ID: 8677079
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Barrett RJ; McGehee R
Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Pizzuto F; Hoskins W
J Clin Oncol; 1992 Feb; 10(2):243-8. PubMed ID: 1732425
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Adcock L; Webster KD; DeEulis T
Invest New Drugs; 1989 Nov; 7(4):341-3. PubMed ID: 2513286
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
Araujo CE; Cervellino JC; Pirisi C; Pannunzio O; Callegari J
J Surg Oncol; 1991 Mar; 46(3):198-202. PubMed ID: 1901372
[TBL] [Abstract][Full Text] [Related]
20. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
